Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion type Assertion NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_head.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion description "[The TOV-21G, TOV-81D, OV-90, and TOV-112D cell lines were derived from ovarian tumors (TOV) or ascites (OV) from chemotherapy- and radiotherapy-naive patients and were characterized by their mutation spectrum of BRCA2, TGFbeta-RII, KRAS2, TP53, and CDKN2A.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_provenance.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion evidence source_evidence_literature NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_provenance.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion SIO_000772 15258697 NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_provenance.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion wasDerivedFrom befree-2016 NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_provenance.
- NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_assertion wasGeneratedBy ECO_0000203 NP452430.RAyl7EASVjGeaqJEA_0A-ZYSe0Lb4xn0bwejBHS66KUf4130_provenance.